{
    "clinical_study": {
        "@rank": "26716", 
        "acronym": "wCCyd", 
        "arm_group": {
            "arm_group_label": "CCyd", 
            "arm_group_type": "Experimental", 
            "description": "Treatment schedule for 9 cycles of induction:\nCyclophosphamide  given orally at the dose of 300 mg/m2 on days 1, 8, 15.\nDexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23.\nCarfilzomib given 20 mg/m2 IV once daily on Day 1 of Cycle 1 only followed by 36/45/56/70 mg/m2 on days 8, 15 of Cycle 1, then for all subsequent doses 70 mg/m2 IV once daily on days 1, 8, 15, followed by 14-day rest period (day 16 through 28).\nTreatment schedule for maintenance until progression or intolerance:\nCarfilzomib at the MTD defined by phase I study IV once daily on days 1, 8, 15."
        }, 
        "brief_summary": {
            "textblock": "This protocol is a phase I/II multicenter study designed to assess the safety and the\n      efficacy of the proposed combinations as up-front treatment in elderly Multiple Myeloma (MM)\n      patients."
        }, 
        "brief_title": "Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "TREATMENT PERIOD Patients will start the induction treatment with wCCyd, as soon as the\n      screening visits of the pre-treatment period have been terminated.\n\n      Each cycle will be repeated every 28 days for a total of 9 courses.\n\n      Treatment schedule for 9 cycles of induction:\n\n      Phase I:\n\n      In the phase I part of the study, the following dose levels of carfilzomib will be studied\n      with constant doses of dexamethasone and cyclophosphamide to define the maximum tolerated\n      dose (MTD):\n\n      Level -1\n\n        1. Cyclophosphamide  given orally at the dose of 300 mg/m2 on days 1, 8, 15.\n\n        2. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days\n           1-2, 8-9,15-16, 22-23.\n\n        3. Carfilzomib given 20 mg/m2 IV once daily on Day 1 of Cycle 1 only followed by 36 mg/m2\n           on days 8, 15 of Cycle 1, then for all subsequent doses 36 mg/m2 IV once daily on days\n           1, 8, 15, followed by 14-day rest period (day 16 through 28).\n\n      Level 0 (starting dose)\n\n        1. Cyclophosphamide  given orally at the dose of 300 mg/m2 on days 1, 8, 15.\n\n        2. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days\n           1-2, 8-9,15-16, 22-23.\n\n        3. Carfilzomib given 20 mg/m2 IV once daily on Day 1 of Cycle 1 only followed by 45 mg/m2\n           on days 8, 15 of Cycle 1, then for all subsequent doses 45 mg/m2 IV once daily on days\n           1, 8, 15, followed by 14-day rest period (day 16 through 28).\n\n      Level +1\n\n        1. Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15.\n\n        2. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days\n           1-2, 8-9,15-16, 22-23.\n\n        3. Carfilzomib given 20 mg/m2 IV once daily on Day 1 of Cycle 1 only followed by 56 mg/m2\n           on days 8, 15 of Cycle 1, then for all subsequent doses 56 mg/m2 IV once daily on days\n           1, 8, 15, followed by 14-day rest period (day 16 through 28).\n\n      Level +2\n\n        1. Cyclophosphamide  given orally at the dose of 300 mg/m2 on days 1, 8, 15.\n\n        2. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days\n           1-2, 8-9,15-16, 22-23.\n\n        3. Carfilzomib given 20 mg/m2 IV once daily on Day 1 of Cycle 1 only followed by 70 mg/m2\n           on days 8, 15 of Cycle 1, then for all subsequent doses 70 mg/m2 IV once daily on days\n           1, 8, 15, followed by 14-day rest period (day 16 through 28).\n\n      Patients will be observed during the first cycle of therapy for the assessment of side\n      effects and observation of DLTs. Dose escalation will proceed as follows:\n\n        -  3 patients will be entered at dose level 0.\n\n        -  If 0/3 patients experience DLT, dose escalation will continue.\n\n        -  If 1/3 patients experience DLT, 3 additional patients will be added to this cohort (max\n           6).\n\n        -  If no further patients experience DLT (1/6) dose escalation will continue.\n\n        -  If 2/6 patients experience DLT, the MTD will have been exceeded and the MTD will be the\n           previous dose at which < 2/6 experienced DLT.\n\n        -  If 2/3 patients experience a DLT at any given dose, the MTD will have been exceeded and\n           the MTD will be the preceding dose at which < 2/6 (or 1/3) patients experienced a DLT.\n\n      Phase II:\n\n      The dose used to treat patients in the phase II will be the MTD defined in the phase I of\n      the study.\n\n      MAINTENANCE PERIOD At the end of the induction phase, patients will start the maintenance\n      phase with Carfilzomib at the MTD defined by the phase I study IV once daily on days 1, 8,\n      15 until progression or intolerance.\n\n      Treatment schedule for maintenance until progression or intolerance:\n\n      Carfilzomib at the MTD defined by phase I study IV once daily on days 1, 8, 15."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Disease-related\n\n          1. Patient is a newly diagnosed MM patient.\n\n          2. Patient is age \u2265 65 year of age or who are ineligible for autologous stem cell\n             transplantation.\n\n          3. Patient has measurable disease, defined as follows: any quantifiable serum monoclonal\n             protein value (generally, but not necessarily, \u2265 0.5 g/dL of M-protein) and, where\n             applicable, urine light-chain excretion of > 200 mg/24 hours. For patients with\n             oligo- or non-secretory MM, it is required that they have measurable plasmacytoma > 2\n             cm as determined by clinical examination or applicable radiographs (i.e. MRI,\n             CT-Scan) or an abnormal free light chain ratio (n.v.: 0.26-1.65). We anticipate that\n             less than 10% of patients admitted to this study will be oligo- or non-secretory MM\n             with free light chains only in order to maximize interpretation of benefit results.\n\n             Demographic:\n\n          4. Age \u2265 18 years.\n\n          5. Life expectancy \u2265 3 months.\n\n          6. Eastern Cooperative Oncology Group (ECOG) performance status 0-2  (Appendix F).\n\n             Laboratory:\n\n          7. Adequate hepatic function, with serum ALT \u2264 3.5 times the upper limit of normal and\n             serum direct bilirubin \u2264 2 mg/dL (34 \u00b5mol/L) within 14 days prior to randomization.\n\n          8. Absolute neutrophil count (ANC) \u2265 1.0 \u00d7 109/L within 14 days prior to randomization.\n\n          9. Corrected serum calcium \u2264 14 mg/dL (3.5 mmol/L).\n\n         10. Alanine transaminase (ALT): \u2264 3 x the ULN.\n\n         11. Hemoglobin \u2265 8 g/dL (80 g/L) within 14 days prior to randomization (subjects may be\n             receiving red blood cell [RBC] transfusions in accordance with institutional\n             guidelines).\n\n         12. Platelet count \u2265 50 \u00d7 109/L  (\u2265 30 \u00d7 109/L if myeloma involvement in the bone marrow\n             is > 50%) within 14 days prior to randomization.\n\n         13. Creatinine clearance (CrCl) \u2265 15 mL/minute within 7 days prior to randomization,\n             either measured or calculated using a standard formula (eg, Cockcroft and Gault).\n\n             Ethical/Other:\n\n         14. Written informed consent in accordance with federal, local, and institutional\n             guidelines.\n\n         15. Females of childbearing potential (FCBP) must agree to ongoing pregnancy testing and\n             to practice contraception.\n\n         16. Male subjects must agree to practice contraception.\n\n        Exclusion Criteria:\n\n        Disease-related:\n\n          1. Previous treatment with anti-myeloma therapy (does not include radiotherapy,\n             bisphosphonates, or a single short course of steroid; \u2264 to the equivalent of\n             dexamethasone 40 mg/day for 4 days)\n\n          2. Patient with relapsed or refractory multiple myeloma.\n\n          3. Patients with non-secretory MM unless serum free light chains are present and the\n             ratio is abnormal.\n\n             Concurrent Conditions:\n\n          4. Pregnant or lactating females (Appendix I).\n\n          5. Major surgery within 21 days prior to randomization.\n\n          6. Acute active infection requiring treatment (systemic antibiotics, antivirals, or\n             antifungals) within 14 days prior to randomization.\n\n          7. Known human immunodeficiency virus infection.\n\n          8. Active hepatitis B or C infection.\n\n          9. Unstable angina or myocardial infarction within 4 months prior to randomization, NYHA\n             Class III or IV heart failure, uncontrolled angina, history of severe coronary artery\n             disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or\n             electrocardiographic evidence of acute ischemia or Grade 3 conduction system\n             abnormalities unless subject has a pacemaker.\n\n         10. Uncontrolled hypertension, uncontrolled congestive heart failure (CHF) or\n             uncontrolled diabetes within 14 days prior to randomization.\n\n         11. Non-hematologic malignancy within the past 3 years with the exception of a)\n             adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid\n             cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason\n             Grade 6 or less with stable prostate-specific antigen levels; or d) cancer considered\n             cured by surgical resection or unlikely to impact survival during the duration of the\n             study, such as localized transitional cell carcinoma of the bladder or benign tumors\n             of the adrenal or pancreas.\n\n         12. Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to\n             randomization.\n\n         13. Known history of allergy to Captisol\u00ae (a cyclodextrin derivative used to solubilize\n             carfilzomib).\n\n         14. Contraindication to any of the required concomitant drugs or supportive treatments,\n             including hypersensitivity to all anticoagulation and antiplatelet options, antiviral\n             drugs, or intolerance to hydration due to preexisting pulmonary or cardiac\n             impairment.\n\n         15. Subjects with pleural effusions requiring thoracentesis or ascites requiring\n             paracentesis within 14 days prior to randomization.\n\n         16. Any other clinically significant medical disease or condition that, in the\n             Investigator's opinion, may interfere with protocol adherence or a subject's ability\n             to give informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "71", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01857115", 
            "org_study_id": "IST-CAR-561"
        }, 
        "intervention": [
            {
                "arm_group_label": "CCyd", 
                "intervention_name": "Carfilzomib", 
                "intervention_type": "Drug", 
                "other_name": "Krypolis"
            }, 
            {
                "arm_group_label": "CCyd", 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug", 
                "other_name": "Endoxan"
            }, 
            {
                "arm_group_label": "CCyd", 
                "intervention_name": "Dexamethasone", 
                "intervention_type": "Drug", 
                "other_name": "Decadron"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Dexamethasone", 
                "Dexamethasone acetate", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Multiple myeloma", 
            "Diagnosis", 
            "Weekly", 
            "CCyd"
        ], 
        "lastchanged_date": "May 17, 2013", 
        "location": {
            "contact": {
                "email": "gismm2001@yahoo.com", 
                "last_name": "Lorenzo Perinetto, Rag.", 
                "phone": "+390116336107"
            }, 
            "facility": {
                "address": {
                    "city": "Torino", 
                    "country": "Italy", 
                    "zip": "10126"
                }, 
                "name": "FO.NE.SA.Onlus"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "A MULTICENTER, OPEN LABEL STUDY OF WEEKLY CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (wCCyd) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS", 
        "overall_contact": {
            "email": "gismm2001@yahoo.com", 
            "last_name": "Lorenzo Perinetto, Rag.", 
            "phone": "+390116336107"
        }, 
        "overall_contact_backup": {
            "email": "gismm2001@yahoo.com", 
            "last_name": "Ufficio Sperimentazioni Cliniche", 
            "phone": "+390116336107"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ministry of Health"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Non-hematologic:\nGrade2 neuropathy with pain\nany Grade 3 toxicity (excluding nausea, vomiting, diarrhea)\nGrade3 nausea, vomiting, or diarrhea despite maximal antiemetic/antidiarrheal therapy\nGrade4 fatigue lasting for \u22657days\nAny non-hematologic toxicity requiring a dose reduction within Cycle1\nInability to receive Day 1 dose of Cycle2 due to drug related toxicity persisting from Cycle1 or drug related toxicity newly encountered on Day1 of Cycle2.\nHematologic:\nGrade 4 neutropenia (ANC<0.5x109/L) lasting for \u22657days\nFebrile neutropenia (ANC<1.0x109/L with a fever \u226538.3\u00baC)\nGrade 4 thrombocytopenia (platelets<25.0x109/L) lasting \u22657 days despite dose delay\nGrade 3-4 thrombocytopenia associated with bleeding\nAny hematologic toxicity requiring a dose reduction within Cycle1\nInability to receive Day1 dose of Cycle2 due to drug related toxicity persisting from Cycle1 or drug related toxicity newly encountered on Day1 of Cycle2.", 
                "measure": "Identification of Dose-limiting toxicity (DLT)", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "The primary efficacy endpoints will be assessed by considering  partial response (PR) following the proposed regimen, at the end of third cycle.", 
                "measure": "Partial Response (PR)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01857115"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Determine the response rate", 
                "measure": "Response rate (RR)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Determine progression free-survival", 
                "measure": "Progression free-survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Determine the time to progression", 
                "measure": "Time to progression (TTP)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Determine the duration of response", 
                "measure": "Duration of response (DOR)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Determine the overall survival", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Determine the time to next therapy", 
                "measure": "Time to next therapy (TTNT)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Determine whether responses obtained with wCCyd treatment are associated with a prolongation of PFS, in comparison with non-responding patients", 
                "measure": "Responses", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Determine whether tumor response and survival might significantly change in particular subgroups of patients defined on prognostic factors (\u03b22-microglobulin, C-reactive protein (CRP), FISH, gene expression profile)", 
                "measure": "Response and survival", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Determine the benefit on PFS and OS of maintenance with Carfilzomib\nDetermine the benefit on tumor load of maintenance with Carfilzomib", 
                "measure": "Maintenance", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Stichting Hemato-Oncologie voor Volwassenen Nederland", 
        "sponsors": {
            "collaborator": {
                "agency": "Fondazione Neoplasie Sangue Onlus", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Stichting Hemato-Oncologie voor Volwassenen Nederland", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}